SAN JUAN CAPISTRANO, Calif., Aug. 21, 2007 (PRIME NEWSWIRE) -- American Mold Guard, Inc. (Nasdaq:AMGI), an industry leader in the field of antimicrobial surface treatment services, announced today through its wholly owned subsidiary, AMG Scientific, LLC, that its antimicrobial environmental treatment will be evaluated at the University of Maryland Medical Center in Baltimore. The goal of the study will be to determine the treatment's effectiveness in infection control on environmental surfaces in intensive care unit rooms. The study, conducted by researchers from the University of Maryland School of Medicine, will look at whether using the product on environmental surfaces reduces contamination by several healthcare-associated pathogens.
The study will also assess whether there is a decreased incidence of contamination of healthcare workers' hands and clothing. Both environmental and healthcare worker contamination have been shown to increase the risk of patient acquired infections.
Dr. Harold Standiford, medical director for infection control at the University of Maryland Medical Center in Baltimore, who is also a professor of medicine at the University of Maryland School of Medicine, will oversee the research study.
The study is planned to begin in early September and is expected to be conducted over a five month period.
"We are pleased to be working with AMG Scientific to see if its antimicrobial surface treatment service will have a meaningful impact toward the reduction of surface transmitted microbes in a hospital environment," said Dr. Standiford. "The health of our patients is our top priority at the University of Maryland Medical Center and we are always interested in strategies to enhance patient safety," Dr. Standiford added.
"We are excited to begin the study and to be working with Dr. Standiford and his team and believe that our services will contribute significantly to the overall reduction of hospital-acquired infections," said Dr. Atif Malik, Chief Science Officer for AMG Scientific.
"This study will help quantify a key component in our overall surface treatment strategy towards the reduction of hospital-acquired infections," said Tom Blakeley, Chief Executive Officer of AMG Scientific.
About American Mold Guard and AMG Scientific, LLC
American Mold Guard, Inc. (Nasdaq:AMGI), founded in 2002, is the industry leader in the field of antimicrobial surface treatment services. AMG Scientific, LLC is a wholly owned subsidiary of AMGI. Established in October 2006, AMG Scientific, LLC is focused on providing long-term antimicrobial infection control services to health care facilities and large institutions in an effort to provide an additional intervention safety net in the fight against hospital-acquired infections. Visit: www.amgscientific.com or www.americanmoldguard.com
The American Mold Guard, Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2964
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company's financial position, results of operations, market position, product and service development and market strategy. These statements may be identified by the fact that they use words or phrases such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "will likely result," "will continue," "may," "could" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, competitive product and service development, the ability to fully develop the company's surface infection control services, future broad market acceptance of antimicrobial surface treatment services, difficulties in raising additional capital in the future, difficulties and delays in establishing the "Mold Guard" brand, the impact of the absence of significant proprietary technology underlying our services, changes in the anticipated size or trends of the markets in which we compete, judicial decisions and governmental laws and regulations, and changes in general economic conditions in the markets in which we may compete. For further details and a discussion of these and other risks and uncertainties, see our periodic reports including current reports on Form 8-K, quarterly reports on Form 10-QSB and our annual report on Form 10-KSB, furnished to and filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.